News

January 25, 2019

Recruitment Begins in Phase 1 Trial of C-CAR088 for Multiple Myeloma

News

A Phase 1 trial in China is recruiting multiple myeloma patients who failed prior treatments to study Cellular Biomedicine’s CAR T-cell product, C-CAR088. The trial is for patients who ... Read more

January 23, 2019

CLR 131 Significantly Extends Survival of Heavily Treated Multiple Myeloma Patients in Phase 1 Trial

News

Heavily treated multiple myeloma patients included in the first four dosing groups of Cellectar Biosciences’ Phase 1 trial lived for a median of 22 months after receiving a single dose ... Read more

January 21, 2019

Ayala Partnering with Novartis on Investigational AL102 for Treatment of Multiple Myeloma

News

In a new agreement, Ayala Pharmaceuticals will work with Novartis on the development and commercialization of AL102, an investigational treatment for multiple myeloma. The option-to-license deal calls for Ayala ... Read more

January 18, 2019

Revlimid Maintenance Extends Survival Without Disease Worsening in Myeloma Patients, Phase 3 Trial Shows

News

Long-term maintenance treatment with Revlimid (lenalidomide) significantly improves the length of time multiple myeloma patients live without disease worsening after their first-line therapy and, in some patients, also extends ... Read more

January 14, 2019

First Patient Treated with Phase 1 Trial Combo of Reolysin, Opdivo, and Kyprolis

News

A Phase 1 trial of the combination of Reolysin (pelareorep), Kyprolis (carfilzomib), and Opdivo (nivolumab) in relapsed multiple myeloma treated the first patient. The open-label, dose escalation study (NCT03605719) will ... Read more

January 11, 2019

Study Tracing Myeloma Progression from Precursor Conditions Seeks Participants

News

A study is recruiting participants to examine the molecular changes that occur when precursor conditions develop into full-blown multiple myeloma, information that can then be used to design therapies ... Read more

January 9, 2019

Janssen Seeks Darzalex Approval for Certain Newly Diagnosed Multiple Myeloma Patients in Japan

News

Janssen Pharmaceutical has submitted an application to Japanese authorities requesting that Darzalex (daratumumab) be approved, in combination with standard therapy, to treat newly diagnosed multiple myeloma patients who cannot receive a stem cell transplant. ... Read more

January 7, 2019

Split Dosing Regimen of Darzalex Approved in Europe for Multiple Myeloma Patients

News

The European Commission has approved a new dosing regimen of the treatment Darzalex (daratumumab), allowing doctors to split the first infusion over two consecutive days, according to Janssen. The approval ... Read more

January 4, 2019

Aplidin Approved in Australia for Relapsed or Refractory Multiple Myeloma

News

Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have failed or are resistant to other therapies. The decision by the Therapeutic ... Read more

January 2, 2019

Triple Combo Therapy May Slow Smoldering Multiple Myeloma Progression into Overt Myeloma, Phase 2 Trial Shows

News

Early treatment with a triple combination therapy containing Empliciti (elotuzumab), Revlimid (lenalidomide), and dexamethasone in patients with smoldering multiple myeloma — a precursor of multiple myeloma — may halt the disease’s ... Read more

Pin It on Pinterest